

## IMPORTANT INFORMATION FOR HEALTHCARE PROFESSIONALS

ABRAXANE (paclitaxel albumin) 100mg presentation, 5 mg/ml - powder for dispersion for infusion:

UK (GB) Notification of Product Shortage

January 2023

Dear Healthcare Professional,

Bristol-Myers Squibb Pharma (BMS) EEIG, regrets to inform you that we are facing a stock shortage of Abraxane (*paclitaxel albumin*) 100mg presentation, 5 mg/ml - powder for dispersion for infusion, within the UK (GB) market. The supply shortage is related to a temporary production issue. It is not related to a quality defect of the product or a safety issue.

It is likely that this stock shortage may restrict availability between now and the end of February 2023.

BMS recognises the importance of Abraxane (*paclitaxel albumin*) to patients and is doing everything we can to minimise the interruption in supply. To help us manage stocks in the coming weeks we would ask that you consider prioritising the ordering of Abraxane for patients who have the greatest need for this product with no other alternatives.

**Please ensure all relevant staff and patients are made aware of the content of this letter.**

For further details on the product, please refer to the approved Summary of Product Characteristics (SmPC) and the Patient Leaflet available at <https://www.medicines.org.uk/emc>.

### Call for Reporting

Reporting suspected adverse reactions after authorisation of a medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.

Please report suspected adverse drug reactions (ADRs) or suspected defective medicines to the MHRA through the Yellow Card Scheme.

You can report via:

- the Yellow Card website [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)
- the free Yellow Card app available from the Apple App Store or Google Play Store
- some clinical IT systems (EMIS/SystemOne/Vision/MiDatabank) for healthcare professionals

Page 2/2 Alternatively, you can report a suspected ADR to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9 am and 5 pm. You can leave a message outside of these hours.


When reporting please provide as much information as possible. By reporting ADRs, you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Bristol Myers Squibb Medical Information on 0800 731 1736 or [medical.information@bms.com](mailto:medical.information@bms.com).

#### Company Contact Point

If you have any medical questions in relation to Abraxane (paclitaxel albumin), please contact the BMS Medical Information department at 0800 731 1736 or via email at [medical.information@bms.com](mailto:medical.information@bms.com)

Sincerely,



Dr. Robert Braun, M.D., M.B.A.  
Director, UK & IRE Disease Area Head for Haematology-Oncology

Bristol Myers Squibb  
ARC Uxbridge  
Sanderson Road  
New Denham, Denham, Buckinghamshire  
UB8 1DH United Kingdom

Job code: 2013-GB-2300003  
Date of preparation: Jan 2023